BPC-157
Body Protective Compound 157 · BPC157 · Bepecin · Pentadecapeptide BPC 157
Next Pep Pro
Unlock your personalised peptide analysis based on your health profile & goals.
BPC-157 (Body Protective Compound 157) is a synthetic pentadecapeptide derived from a protein sequence found in human gastric juice. It operates through four verified molecular mechanisms: (1) VEGFR2–PI3K–Akt–eNOS angiogenesis — BPC-157 upregulates VEGF receptor-2 activity, driving capillary formation at injury sites via nitric oxide; (2) a second, VEGF-independent Src–caveolin-1–eNOS angiogenesis pathway that operates even in low-VEGF environments; (3) FAK-paxillin cell migration — modulation of focal adhesion kinase and paxillin accelerates fibroblast and endothelial migration toward wounds; and (4) growth hormone receptor upregulation at injury sites, restoring local GHR density without elevating systemic GH levels. These four mechanisms act in concert across musculoskeletal, gastrointestinal, and CNS tissue in preclinical models.
In-depth Research Guide
BPC-157: The Complete Research Guide for 2026
In-depth Research Guide
BPC-157 vs TB-500: Mechanism, Evidence, and When Each Makes Sense
The 2025 systematic review by Vasireddi et al. (AAOS Orthopaedic Sports Medicine) screened 544 peer-reviewed articles and identified 36 qualifying studies: 35 preclinical (rodent and dog models) and exactly 1 human trial. This 35:1 ratio is the defining characteristic of the BPC-157 evidence base. All preclinical data is consistently positive across musculoskeletal, GI, and neurological outcomes. A 2025 IV safety study in two healthy human volunteers administered doses up to 20 mg without adverse events — the highest quality human safety data currently available, but from only two subjects. A Phase I trial (NCT02637284) in 42 healthy volunteers was initiated circa 2015 and cancelled in 2016 with no data published.
BPC-157Also known as: Body Protective Compound 157, BPC157, Bepecin, Pentadecapeptide BPC 157
Mechanism of Action
BPC-157 (Body Protective Compound 157) is a synthetic pentadecapeptide derived from a protein sequence found in human gastric juice. It operates through four verified molecular mechanisms: (1) VEGFR2–PI3K–Akt–eNOS angiogenesis — BPC-157 upregulates VEGF receptor-2 activity, driving capillary formation at injury sites via nitric oxide; (2) a second, VEGF-independent Src–caveolin-1–eNOS angiogenesis pathway that operates even in low-VEGF environments; (3) FAK-paxillin cell migration — modulation of focal adhesion kinase and paxillin accelerates fibroblast and endothelial migration toward wounds; and (4) growth hormone receptor upregulation at injury sites, restoring local GHR density without elevating systemic GH levels. These four mechanisms act in concert across musculoskeletal, gastrointestinal, and CNS tissue in preclinical models.
Reported Research Benefits
- Accelerated tendon and ligament repair in multiple rodent injury models (Achilles, patellar, transected tendons)
- Gastrointestinal cytoprotection — reduces NSAID-induced damage, promotes mucosal healing in IBD and ulcer models
- Bone fracture healing via enhanced periosteal vascularisation and collagen synthesis
- CNS protection — anxiolytic and antidepressant-like effects in rodent models via dopaminergic and serotonergic modulation
- VEGF-independent angiogenesis through dual eNOS activation pathways (Sikiric et al., PMC 2025)
- Gastric acid stability (>24 hours) enabling effective oral delivery for GI applications
Dosing Protocol & Reconstitution
Reported Research Dosing — Not Clinical Recommendations
No FDA-approved dosing protocol exists for BPC-157. The ranges below are extrapolated from rodent studies scaled to human bodyweight using allometric conversion, and reflect the most commonly cited research-protocol doses in the practitioner literature.
Dosing by Route
| Route | Starting Dose | Common Range | Frequency | Typical Cycle |
|---|---|---|---|---|
| Subcutaneous (musculoskeletal) | 200–250 mcg | 250–500 mcg/day | 1–2× daily | 4–8 weeks |
| Subcutaneous (near injury site) | 200 mcg | 200–400 mcg/site | 1× daily | 4–6 weeks |
| Oral (GI applications) | 500 mcg | 500–1,500 mcg/day | 1× daily on empty stomach | 4–8 weeks |
Protocol Timeline
Weeks 1–2 (ramp): 200–250 mcg once daily subcutaneous. Establishes tolerance baseline and detects any injection-site reactivity.
Weeks 3–6 (maintenance): titrate to 250–500 mcg/day. Musculoskeletal research protocols typically inject locally (within 1–2 cm of the target tissue) once or twice daily. Higher end of range for larger tissue volumes or more chronic injuries.
Weeks 7–8 (taper) + 2–4 week washout: reduce to 200 mcg/day for final week, then pause. Rotation breaks are standard practitioner practice — not based on clinical data, but align with the general principle of avoiding continuous peptide exposure.
Reconstitution
- 5 mg vial + 2 mL bacteriostatic water = 2,500 mcg/mL (500 mcg per 0.2 mL; 250 mcg per 0.1 mL).
- 10 mg vial + 2 mL bacteriostatic water = 5,000 mcg/mL (500 mcg per 0.1 mL).
- Use insulin syringes (U-100) for accurate micro-dosing.
- Reconstituted solution stable 28 days refrigerated at 2–8°C.
- See the dosing calculator for draw-volume conversion.
Contraindications and Cautions
- Active malignancy: BPC-157's angiogenic activity is a theoretical concern in tumour tissue, though no tumour-promoting effects have been observed in preclinical studies. Oncology populations have not been formally studied.
- Pregnancy and lactation: no data; avoid.
- Active infection: FAK-paxillin modulation and angiogenesis may interact with inflammatory responses in unknown ways.
- Drug interactions: not characterised. Caution with anticoagulants, anti-VEGF therapies, and concurrent growth-factor treatments.
- WADA status: prohibited in competitive sport.
What the Evidence Actually Supports
The 2025 AAOS systematic review (Vasireddi et al.) identified 35 preclinical and only 1 human study meeting inclusion criteria. The 2025 IV safety study tolerated doses up to 20 mg IV in two healthy volunteers without adverse events — the highest-quality published human safety data. All dose ranges above are extrapolations from preclinical literature, not validated human clinical protocols.
Research Notes
The 2025 systematic review by Vasireddi et al. (AAOS Orthopaedic Sports Medicine) screened 544 peer-reviewed articles and identified 36 qualifying studies: 35 preclinical (rodent and dog models) and exactly 1 human trial. This 35:1 ratio is the defining characteristic of the BPC-157 evidence base. All preclinical data is consistently positive across musculoskeletal, GI, and neurological outcomes. A 2025 IV safety study in two healthy human volunteers administered doses up to 20 mg without adverse events — the highest quality human safety data currently available, but from only two subjects. A Phase I trial (NCT02637284) in 42 healthy volunteers was initiated circa 2015 and cancelled in 2016 with no data published.
Research Summary
Vasireddi et al. (Orthopaedic Sports Medicine, SAGE Journals, 2025) reviewed 544 studies on BPC-157 and found 36 qualifying trials: 35 preclinical (animal) and 1 human pilot. The preclinical literature shows consistent efficacy across musculoskeletal, GI, and neurological injury models spanning 30+ years. Human evidence is too limited for clinical conclusions. A 2025 IV safety study (Lee & Burgess, Alternative Therapies / PubMed) administered up to 20 mg IV in healthy adults with no adverse events recorded across cardiac, hepatic, renal, and thyroid biomarkers.
Side Effects & Safety
Animal safety record: no significant toxicity signals across 30+ years of preclinical dosing studies. Human data: two healthy adults tolerated 20 mg IV without adverse events (Lee & Burgess, 2025) — the only formal human safety data. Reported in clinical practice: GI discomfort (most common, transient), injection site reactions (mild erythema, transient). Theoretical concerns: angiogenic activity warrants caution in patients with active malignancy (no tumour-promoting effects observed in any preclinical study, but oncology populations have not been formally studied). Drug interactions: not characterised. WADA prohibited in competitive sport.
Stability & Storage
Lyophilised powder: stable at -20°C for 3–5 years; at 4°C for up to 12 months. After reconstitution with bacteriostatic water: store at 4°C, use within 28 days. Do not freeze reconstituted solution. Stable in simulated gastric acid for >24 hours.
Molecular Data
- Sequence
- Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
- Molecular Formula
- C62H98N16O22
- Molecular Weight
- 1419.55 Da
- CAS Number
- 137525-51-0
- Half-Life
- IV: 15.2 min (rat), 5.27 min (dog) · SubQ: ~45 min (dog) · IM: ~30 min (dog) · Gastric acid stability: >24 hours
Primary literature: https://pubmed.ncbi.nlm.nih.gov/40131143/